Compare UAMY & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAMY | VOGX |
|---|---|---|
| Founded | 1968 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.0M | 482.8M |
| IPO Year | 1997 | 2026 |
| Metric | UAMY | VOGX |
|---|---|---|
| Price | $2.81 | $17.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.92 | N/A |
| AVG Volume (30 Days) | ★ 6.0M | 69.8K |
| Earning Date | 11-20-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,257,708.00 | N/A |
| Revenue This Year | $65.44 | N/A |
| Revenue Next Year | $210.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 162.80 | N/A |
| 52 Week Low | $2.64 | $13.50 |
| 52 Week High | $12.64 | $38.41 |
| Indicator | UAMY | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 43.83 |
| Support Level | $2.64 | $14.41 |
| Resistance Level | $3.37 | $22.10 |
| Average True Range (ATR) | 0.25 | 2.63 |
| MACD | 0.03 | 0.31 |
| Stochastic Oscillator | 32.76 | 38.73 |
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the Domestic, Canada, and Mexico, of which the vast majority of its revenue comes from the Domestic.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.